Evidence map›Paper›PMID 41582113›Full record

ArticleEJNMMI research2026

Quantitative assessment of graves' ophthalmopathy activity using

Yan Li, Rui Cheng, Zhongyang Yang, Bo Ma, Jiafu Peng, Jinfeng Wang, Haiyan Liu, Keyi Lu, Sijin Li, Bao Li and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yan Li *Department of Nuclear Medicine, The First Hospital of Shanxi Medical University, Shanxi Medical University, No. 85, Jiefang Road, Taiyuan, 030001, Shanxi, P. R. China.
Rui Cheng *Department of Nuclear Medicine, The First Hospital of Shanxi Medical University, Shanxi Medical University, No. 85, Jiefang Road, Taiyuan, 030001, Shanxi, P. R. China.
Zhongyang YangDepartment of Nuclear Medicine, The First Hospital of Shanxi Medical University, Shanxi Medical University, No. 85, Jiefang Road, Taiyuan, 030001, Shanxi, P. R. China.
Bo MaDepartment of Nuclear Medicine, The First Hospital of Shanxi Medical University, Shanxi Medical University, No. 85, Jiefang Road, Taiyuan, 030001, Shanxi, P. R. China.
Jiafu PengDepartment of Nuclear Medicine, The First Hospital of Shanxi Medical University, Shanxi Medical University, No. 85, Jiefang Road, Taiyuan, 030001, Shanxi, P. R. China.
Jinfeng WangDepartment of Nuclear Medicine, The First Hospital of Shanxi Medical University, Shanxi Medical University, No. 85, Jiefang Road, Taiyuan, 030001, Shanxi, P. R. China.
Haiyan LiuDepartment of Nuclear Medicine, The First Hospital of Shanxi Medical University, Shanxi Medical University, No. 85, Jiefang Road, Taiyuan, 030001, Shanxi, P. R. China.
Keyi LuDepartment of Nuclear Medicine, The First Hospital of Shanxi Medical University, Shanxi Medical University, No. 85, Jiefang Road, Taiyuan, 030001, Shanxi, P. R. China.
Sijin LiDepartment of Nuclear Medicine, The First Hospital of Shanxi Medical University, Shanxi Medical University, No. 85, Jiefang Road, Taiyuan, 030001, Shanxi, P. R. China. lisjnm123@163.com.
Bao LiShanxi Medical University Postdoctoral Research Station & The Second Hospital of Shanxi Medical University, No. 382, Wuyi Road, Taiyuan, 030001, Shanxi, P. R. China. libaoxys@163.com.
Hua WeiDepartment of Nuclear Medicine, The First Hospital of Shanxi Medical University, Shanxi Medical University, No. 85, Jiefang Road, Taiyuan, 030001, Shanxi, P. R. China. Jennyhua1981@sina.com.ORCID http://orcid.org/0000-0003-0023-2605

Funding

National Natural Science Foundation of China No. 82027804Shanxi National College Students' Innovation and Entrepreneurship Training Project No. 20230243Shanxi Provincial Health Commission No. 2024050
6 · The paper itself

Abstract

backgroundGraves' ophthalmopathy (GO) is a challenging autoimmune manifestation of Graves' disease, whose management relies on accurate assessment of inflammatory activity in the extraocular muscles (EOMs). The Clinical Activity Score (CAS), the current gold standard for assessing disease activity, is based on subjective clinical signs. Consequently, objective imaging biomarkers are urgently needed as a complement orbital

resultsGroup Differences: EOM uptake values for all four indices were significantly higher in the active GO group than in both the inactive and control groups (all P ＜ 0.001). No significant differences were found between the inactive and control groups. CLINICAL CORRELATION: All quantitative parameters showed significant positive correlations with the CAS (all p ＜ 0.001). DIAGNOSTIC PERFORMANCE: ROC curve analysis confirmed that all indices effectively differentiated active from inactive GO, with SUV

conclusionsIn summary, this study confirms that quantitative indices from orbital

Indexed as

99mTc-DTPAGraves' ophthalmopathy (GO)Orbital imagingSPECT/CT standardized uptake value (SUV)

Identifiers

PMID41582113
PMCPMC12847564

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.